Akebia Therapeutics (AKBA) Return on Invested Capital (2019 - 2026)

Akebia Therapeutics (AKBA) reported Return on Invested Capital of 0.0% for Q1 2026, down 81.46% quarter-over-quarter from 0.0% in Q4 2025.

Akebia Therapeutics (AKBA) Return on Invested Capital (2019 - 2026) Analysis & Trends

Akebia Therapeutics (AKBA) has 4 years of Return on Invested Capital data on file, last reported at 0.0% in Q1 2026.

Return on Invested Capital for Q1 2026 came in at 0.0%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 0.0% (changed N/A YoY), and the FY2025 annual result was 0.01%, changed N/A from the prior year.
Return on Invested Capital declined to 0.0% in Q1 2026 per AKBA's latest filing, from 0.0% in the prior quarter.
Over five years, Return on Invested Capital peaked at 0.0% in Q4 2025 and troughed at 0.0% in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROIC (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn	0.00%
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn	0.01%
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn	0.00%
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn	0.00%
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn	0.00%
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn	0.00%
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn	0.00%
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn	0.00%
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn	0.00%
10	Akebia Therapeutics	243.23 Mn	80.63 Mn	41.25 Mn	0.00%

Download Data